For patients with multiple chronic diseases such as T2DM, HF, and CKD, treatment with SGLT2 inhibitors significantly reduces the risk of nonfatal MI, HHF, and cardiac death, particularly in those with both T2DM and CKD. This evidence concerns the gene SLC5A2 and chronic kidney disease.